Search

Your search keyword '"Hepatocellular"' showing total 4,765 results

Search Constraints

Start Over You searched for: Descriptor "Hepatocellular" Remove constraint Descriptor: "Hepatocellular"
4,765 results on '"Hepatocellular"'

Search Results

1. Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma.

2. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis.

3. Hepatocellular carcinoma after direct‐acting antivirals for hepatitis C is associated with KIR‐HLA types predicting weak NK cell‐mediated immunity

4. Development and validation of a biomarker index for HCC treatment response.

5. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America.

6. Integrative common and rare variant analyses provide insights into the genetic architecture of liver cirrhosis.

7. BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights.

8. Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.

9. Impact of glucose metabolism on PD-L1 expression in sorafenib-resistant hepatocellular carcinoma cells.

10. Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer

11. Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality

12. Assessing Adherence to US LI-RADS Follow-up Recommendations in Vulnerable Patients Undergoing Hepatocellular Carcinoma Surveillance.

13. Recent advances in the management of hepatocellular carcinoma.

14. MRI radiomics to monitor therapeutic outcome of sorafenib plus IHA transcatheter NK cell combination therapy in hepatocellular carcinoma

15. Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma—An ELTR Study.

16. Diagnostic value of serum STIP1 in HCC and AFP-negative HCC.

17. Apparent diffusion coefficient and tissue stiffness are associated with different tumor microenvironment features of hepatocellular carcinoma.

18. DGAT2 Plays a Crucial Role to Control ESRRAPROX1 Transcriptional Network to Maintain Hepatic Mitochondrial Sustainability.

19. 华蟾素调控AKT介导的上皮间质转化抑制肝细胞癌肺转移裸鼠 模型的作用机制.

20. AU富集元件结合因子1(AUF1)在肝细胞癌中的表达 及预后评估价值.

21. 基于生物信息学分析构建肝细胞癌患者新型双硫死亡 相关预后模型.

22. 微波消融与手术切除治疗肝细胞癌合并肝硬化效果及安全性的 Meta分析.

23. 局部治疗联合系统治疗在肝细胞癌转化治疗中的价值.

24. 肝细胞癌转化治疗的策略及实践.

25. 转化治疗时代的肝脏外科治疗模式.

26. Hepatocellular Carcinoma (HCC) Metastasis to the Diaphragm Muscle: A Systematic Review and Meta-Analysis of Case Reports.

27. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation

28. Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study.

29. AFP-L3 and DCP are superior to AFP in predicting waitlist dropout in HCC patients: Results of a prospective study

30. Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma.

31. Contemporary applications of Y90 for the treatment of hepatocellular carcinoma.

32. Childrens Oncology Groups 2023 blueprint for research: Liver tumors.

33. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis

34. Stimulating Antitumoral Immunity by Percutaneous Cryoablation and Combination Immunoadjuvant Therapy in a Murine Model of Hepatocellular Carcinoma

35. Imaging prognostication and tumor biology in hepatocellular carcinoma.

36. Clinical‐Radiologic Morphology‐Radiomics Model on Gadobenate Dimeglumine‐Enhanced MRI for Identification of Highly Aggressive Hepatocellular Carcinoma: Temporal Validation and Multiscanner Validation.

37. Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase

38. Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort

39. Clearance of Hepatitis C Virus following Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma: Case Report

40. Gd-EOB-DTPA enhanced MRI nomogram model to differentiate hepatocellular carcinoma and focal nodular hyperplasia both showing iso- or hyperintensity in the hepatobiliary phase.

41. Anatomic, isolated complete caudate lobectomy using an anterior transhepatic approach with glissonian pedicle approach and indocyanine green fluorescence guidance: a case report.

42. 酪氨酸激酶抑制剂联合免疫检查点抑制剂在中晚期肝细胞癌 二线治疗中的效果及安全性分析.

43. Japanese living donor liver transplantation criteria for hepatocellular carcinoma: nationwide cohort study.

44. Prognostic impact of presenting symptoms of patients with hepatocellular carcinoma.

45. Stereotactic Body Radiotherapy in Bulky Hepatocellular Carcinoma with or without Portal Vein Thrombosis: A Feasibility Review in an Egyptian Cohort.

46. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.

47. 中药抑制肝细胞癌血管生成的作用机制.

48. 三维可视化技术辅助肝细胞癌消融治疗有效性及安全性的 Meta 分析.

49. 细胞周期蛋白依赖性激酶 1 (CDK1) 和极光激酶A (AURKA) 在HBV相关肝细胞癌患者血清中的表达及意义.

50. 《原发性肝癌诊疗指南 (2024年版) 》解读.

Catalog

Books, media, physical & digital resources